Anti-Hypertensive Drugs - Moldova

Moldova

The Anti-Hypertensive Drugs market in Moldova is expected to witness a significant rise in revenue, reaching US$1.29m in 2024.
Furthermore, this market is projected to exhibit a steady annual growth rate of -0.95% from 2024 to 2029, leading to a market volume of US$1.23m by 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in this sector, amounting to US$12,290.00m in 2024.
Moldova has witnessed a surge in the demand for locally produced generic anti-hypertensive drugs due to increasing healthcare costs.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Moldova has been increasing steadily over the past few years.

Customer preferences: Moldova has a high prevalence of hypertension, which is a major risk factor for cardiovascular disease. Due to this, there is a high demand for Anti-Hypertensive Drugs in the country. Patients in Moldova prefer drugs that are effective, affordable and easily accessible.

Trends in the market: The Anti-Hypertensive Drugs market in Moldova is dominated by generic drugs due to their affordability. The market is highly competitive, with many local and international players vying for market share. Recently, there has been a trend towards the use of combination therapy, where two or more drugs are used together to treat hypertension. This is because combination therapy is more effective in controlling blood pressure and reducing the risk of cardiovascular disease.

Local special circumstances: Moldova is a small country with a population of approximately 2.6 million people. The healthcare system in the country is underfunded and lacks resources. This has led to a shortage of healthcare professionals and infrastructure, making it difficult for patients to access healthcare services. The government has been taking steps to improve the healthcare system, but progress has been slow.

Underlying macroeconomic factors: The economy of Moldova is heavily dependent on remittances from abroad, mainly from Russia and other European countries. The country has been experiencing economic difficulties, with high levels of poverty and unemployment. This has led to a lack of access to healthcare services for many Moldovans, particularly those living in rural areas. The government has been working to improve the economy and increase access to healthcare, but progress has been slow.In conclusion, the demand for Anti-Hypertensive Drugs in Moldova is driven by the high prevalence of hypertension in the country. Patients prefer drugs that are effective, affordable and easily accessible. The market is dominated by generic drugs and there is a trend towards the use of combination therapy. The healthcare system in Moldova is underfunded and lacks resources, making it difficult for patients to access healthcare services. The economy of Moldova is heavily dependent on remittances from abroad and the country has been experiencing economic difficulties, which has led to a lack of access to healthcare services for many Moldovans.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.